Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.

Autor: Alvarez-Manceñido F; Pharmacy Department, Hospital Universitario Central de Asturias, Avenida Roma s/n, 33011, Oviedo, Spain. felipealvarezm@yahoo.es., Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain., Carmona-Bayonas A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain., Arrazubi V; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain., Hernandez R; Medical Oncology Department, Hospital Universitario de Canarias, Tenerife, Spain., Cano JM; Medical Oncology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., Custodio A; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain., Pericay Pijaume C; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain., Aguado G; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain., Martínez Lago N; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Sánchez Cánovas M; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain., Cacho Lavin D; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain., Visa L; Medical Oncology Department, Hospital Universitario El Mar, Barcelona, Spain., Martinez-Torron A; Pharmacy Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Arias-Martinez A; Pharmacy Department, Hospital Universitario Central de Asturias, Avenida Roma s/n, 33011, Oviedo, Spain., López F; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain., Limón ML; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Vidal Tocino R; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain., Fernández Montes A; Medical Oncology Department, Complejo Hospitalario de Orense, Orense, Spain., Alsina M; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pimentel P; Medical Oncology Department, Hospital General Universitario Santa Lucía, Cartagena, Spain., Reguera P; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain., Martín Carnicero A; Medical Oncology Department, Hospital San Pedro, Logroño, Spain., Ramchandani A; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain., Granja M; Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain., Azkarate A; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain., Martín Richard M; Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain., Serra O; Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet, Spain., Hernández Pérez C; Medical Oncology Department, Hospital Universitario Nuestra Señora de la Candelaria, Tenerife, Spain., Hurtado A; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Gil-Negrete A; Medical Oncology Department, Hospital Universitario Donostia, San Sebastián, Spain., Sauri T; Medical Oncology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain., Morales Del Burgo P; Pathology Department, Hospital Universitario Central de Asturias, Oviedo, Spain., Gallego J; Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain.

Publikováno v: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2021 Jul; Vol. 24 (4), pp. 926-936. Date of Electronic Publication: 2021 Mar 02.

P-190 - Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients

Autor: de Toro Carmena, M., Ortega Morán, L., García Adrián, S., Castañón López, C., Molina Villaverde, R., Marrupe González, D., Lopez Muñoz, A., Alcaraz Nunes, D., Díaz Beveridge, R., López Alfonso, A., García Paredes, B., Fernández Montes, A., Soriano Rodríguez, M., Encinas García, S., Alcaide García, J., Pericay Pijaume, C., Macarulla Mercadé, T., Rodríguez-Salas, N., García Alfonso, P., Muñoz Martín, A.

Publikováno v: In Annals of Oncology July 2019 30 Supplement 4:iv51-iv52

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intervention in gastrointestinal stromal tumour with a high risk of malignancy and associated with thalassaemia minor.

Autor: Pericay Pijaume C; Medical Oncology Department, Sabadell Universitary Hospital-CSUPT, Sabadell, Barcelona, Spain. cpericay@gmail.com, Saigi Grau E

Publikováno v: Anti-cancer drugs [Anticancer Drugs] 2012 Jun; Vol. 23 Suppl, pp. S13-4.

Haemolytic uraemic syndrome associated with gemcitabine.

Autor: Moya-Horno I; Medical Oncology Service, Hospital de Sabadell, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain., Querol Niñerola R, Bonfill Abella T, Dalmau Pórtulas E, Gallardo-Díaz E, Saigí Grau E, Pericay Pijaume C

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2010 May; Vol. 12 (5), pp. 381-3.